Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.

被引：6
|
作者：
Boileve, Alice
Baiev, Islam
Dinicola, Caroline
Horick, Nora K.
Tazdait, Melodie
Zhu, Andrew X.
Hollebecque, Antoine
Goyal, Lipika
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Gustave Roussy, Med Imaging, Villejuif, France
[4] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Ctr, Boston, MA USA
[5] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4084
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
    Varghese, Anna M.
    Patel, Juber Ahamad A.
    Janjigian, Yelena Yuriy
    Meng, Fanli
    Selcuklu, S. Duygu
    Zimel, Catherine
    Hyman, David Michael
    Iyer, Gopa
    Houck-Loomis, Brian
    Abou-Alfa, Ghassan K.
    Berger, Michael F.
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
    Varghese, Anna M.
    Patel, Juber
    Janjigian, Yelena Y.
    Meng, Fanli
    Selcuklu, S. Duygu
    Iyer, Gopakumar
    Houck-Loomis, Brian
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    Lowery, Maeve A.
    Berger, Michael F.
    JCO PRECISION ONCOLOGY, 2021, 5 : 44 - 50
  • [3] Radiation-induced astrocytomas: Clinicopathologic features and molecular genetic alterations.
    Brat, DJ
    Jedlicka, AE
    Connolly, DC
    Cho, KR
    Castellani, RJ
    Burger, PC
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (05): : 469 - 469
  • [4] Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
    Park, Joon Oh
    Feng, Yin-Hsun
    Chen, Yen-Yang
    Su, Wu-Chou
    Oh, Do-Youn
    Shen, Lin
    Kim, Kyu-Pyo
    Liu, Xiufeng
    Bai, Yuxian
    Liao, Huimin
    Nie, Jing
    Qing, Min
    Ji, Qinmei
    Li, Jiongyan
    Zhao, Mianzhi
    De Porre, Peter
    Monga, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.
    Ciombor, Kristen Keon
    Zemla, Tyler J.
    Hubbard, Joleen M.
    Jia, Jingquan
    Gbolahan, Olumide B.
    Sousa, Andrea
    Wilson, Luke
    Waechter, Blake
    Ou, Fang-Shu
    Nixon, Andrew B.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 139 - 139
  • [6] Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features
    Zhou, Jun
    Yu, Haoran
    Zeng, Hong
    Shen, Qin
    Wang, Xuewen
    Xia, Qinxin
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (12) : 2125 - 2132
  • [7] Diffuse gliomas with FGFR alterations, histopathological features, genetic alterations, and potential clinical implications
    El Achi, Hanadi
    Dono, Antonio
    Zhu, Ping
    Bundrant, Bethany
    Esquenazi, Yoshua
    Ballester, Leomar
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 656 - 657
  • [8] Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications
    Dono, Antonio
    El Achi, Hanadi
    Bundrant, Bethany E.
    Goli, Puneetha S.
    Zhu, Ping
    Ozkizilkaya, Hanim, I
    Esquenazi, Yoshua
    Ballester, Leomar Y.
    CANCER BIOMARKERS, 2023, 36 (02) : 117 - 131
  • [9] Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
    Guo, Ye
    Yuan, Chunwang
    Ying, Jieer
    Zhu, Xu
    Luan, Guodong
    Zhang, Bin
    Zhao, Renbin
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations.
    Azar, Ibrahim
    Gandhi, Nishant
    Nagasaka, Misako
    Gong, Jun
    Nazha, Bassel
    Choucair, Khalil
    Khushman, Moh'd M.
    Soares, Heloisa P.
    El-Deiry, Wafik S.
    Philip, Agop Philip
    Lou, Emil
    Farrell, Alex Patrick
    Swensen, Jeffrey
    Oberley, Matthew James
    Abraham, Jim
    Nabhan, Chadi
    Goel, Sanjay
    Korn, Wolfgang Michael
    Shields, Anthony Frank
    Azmi, Asfar S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 649 - 649
12345